Q32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibart

Q32 Bio (QTTB) announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata, AA, at the 2025 American Academy of Dermatology, AAD, Meeting in Orlando, FL. Bempikibart is a fully human anti-IL-7Ralpha antibody that re-regulates adaptive immune function by blocking IL-7 and TSLP signaling that is in development for the treatment of AA and currently being evaluated in a Phase 2 program. Results presented in AAD late-breaker demonstrate bempikibart’s encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very severe alopecia areata. Durable, ongoing responses in multiple patients through week 36 follow-up period and beyond to week 55, despite only 24 weeks of dosing, suggestive of potential for remittive effect; multiple inbound patient requests to re-initiate dosing. Bempikibart development program remains on track with open-label extension study to initiate in 1H’25; SIGNAL-AA Part B remains on track for initiation of dosing in 1H’25, with topline data expected in 1H’26.